Infertility Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Infertility Drugs Market is segmented by Drug Class (Gonadotrophins, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Biguanides, and Other Drug Classes), End User (Male and Female), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Other Distribution Channels), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Market Summary
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 6.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The infertility drugs market is expected to register a CAGR of 6.5% over the forecast period (2022-2027).

The outbreak of COVID-19 adversely impacted the market. The disruption in the supply chain during COVID-19 and delay in delivery of essential products required for the manufacturing of infertility drugs imposed an adverse effect on the infertility drugs market. Furthermore, the suspension or delay of fertility treatments during COVID-19 across the globe also hindered the market growth. For instance, according to the study titled, " Suspension of fertility treatment during the COVID-19 pandemic: views, emotional reactions and psychological distress among women undergoing fertility treatment" published by the National Library of Medicine in April 2021, there was a suspension of fertility treatment during the initial phase of the pandemic which caused anxiety and psychological distress among women undergoing fertility treatment. Therefore, such instances indicate that the market witnessed slow growth during the pandemic.

The increasing adoption of a sedentary lifestyle by both men and women across the globe is one of the major factors contributing to the market growth over the forecast period. For instance, according to the report published by the National Center for Drug Abuse Statistics in 2021, around 60.0% of Americans increased their alcohol consumption during the COVID-19 lockdowns. Similarly, as per the report published by the World Health Organization in 2021, more than 300.0 million people in China were smokers which is around one-third of the world’s total population in 2021. Around 26.6% of adult smokers in China were of 15 years of age or above. The sedentary lifestyle is one of the major cause for hormonal imbalance, polycystic ovarian disease and weight issues which directly impacts the embryo, leading to infertility problems. Therefore, increasing adoption of sedentary lifestyle is one of the major drivers for the market.

However, stringent regulatory framework for product approval and expensive patented products are likely to impede the market growth over the forecast period.

Scope of the Report

As per the scope of the report, infertility is the inability of a woman to become pregnant after one year (or longer) of unprotected sex. The fertility rate decreases with the age of 35 or above in both men and women. Medicines that regulate or stimulate ovulation are known as fertility drugs. Fertility drugs are the main treatment for women who are infertile due to ovulation disorders. Fertility drugs generally work with natural hormones, such as follicle-stimulating hormone (FSH) and luteinizing hormone (LH), to trigger ovulation. The infertility drugs market is segmented by Drug Class (Gonadotrophins, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Biguanides, and Other Drug Classes), End User (Male and Female), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Other Distribution Channels), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Drug Class
Gonadotrophins
Aromatase Inhibitors
Selective Estrogen Receptor Modulators (SERMs)
Biguanides
Other Drug Classes
By End User
Male
Female
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Other Distribution Channels
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Female Infertility Drugs Segment is Expected to Witness Growth Over the Forecast Period

The female infertility drugs segment is expected to dominate the industry over the forecast period. The female infertility drugs are used to stimulate ovulation and are meant for treating women who are infertile or have ovulation disorder. Clomiphene citrate, Gonadotropins, Letrozole, Metformin, and Bromocriptine are some of the common female infertility drugs.

The increasing cases of infertility among females are one of the major drivers for the segment. For instance, as per the journal published by Singlecare in February 2022, around 30.0% of infertility cases can be attributed solely to females. Similarly, as per the report published by the World Health Organization in September 2020, 48.0 million couples and 186.0 million individuals are living with infertility across the globe. Furthermore, increasing cases of Polycystic Ovary Syndrome (PCOS) among women are also expected to trigger the segment growth. For instance, as per the study titled, "The Prevalence of Polycystic Ovary Syndrome" in December 2020, polycystic ovary syndrome (PCOS) is the major endocrinopathy among reproductive-aged women and it affects around 4.0%–20.0% of women of reproductive age globally. Therefore, such instances indicate that the demand for female infertility drugs will increase, thereby propelling the segment growth over the forecast period.

1

North America is Expected to Dominate the Infertility Drugs Market Over the Forecast Period

North America is expected to dominate the global infertility drugs market during the forecast period. This dominance is mainly owing to rising incidences of infertility problems, menopausal disorders, urinary infections, thyroid problems, endometriosis, and others due to busy lifestyles and a rise in stress among women. For instance, as per the report published by Statistics Canada in May 2022, fewer babies were born in Canada in 2020 due to the low fertility rate. It also reported that Canada's birth rate fell from 1.47 children per woman in 2019 to a record low of 1.40 children per woman in 2020. Moreover, Canada also witnessed the lowest number of births since 2007 and the greatest year-over-year decrease in births (-3.6%) since 1997. Therefore, such factors are anticipated to increase the sale of infertility drugs in this region, thereby surging the market growth.

High concentration of market players or manufacturer's presence, and acquisition & partnerships among major players, and an increasing number of infertility and PCOS cases in the United States are some of the factors driving the growth of the infertility drugs market in the country. For instance, as per the report published by the Centers for Disease Control and Prevention (CDC) in March 2020, PCOS is one of the most common causes of female infertility and it affects around 6.0% to 12.0% (approx 5.0 million) of women of reproductive age in the United States every year. Therefore such instances, indicate considerable growth of the market in the United States.

Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the North America Region.

1

Competitive Landscape

The global infertility drugs market is moderately competitive and consists of several major players. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known including Ferring Pharmaceuticals Inc., Merck KGaA, Bayer AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Theramex, and Novartis AG among others.

Recent Development

  • In August 2021, Merck launched Pergoveris Pen for fertility treatment in India. The Pergoveris Pen is the first ever product to combine recombinant follicle-stimulating hormone and recombinant luteinizing hormone in a ready-to-use device to be used on prescription by an IVF specialist. A globally approved pen filled with bulk technology provides infertile couples with a safer self-service infertility solution.
  • In November 2021, InsurMedix, an AI-powered insurance platform, is closing a USD 65 million funding round to provide coverage for fertility treatments. Launching in the United States in early 2022, the platform provides medical insurance for fertility treatments including IVF, with coverage for complementary and alternative medicine as well as medical tourism for care outside of the United States to come later in the year.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Defination

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Global Prevalence of Stress and Life-style Disorders among Men and Women

      2. 4.2.2 Rise in Healthcare Awareness along with Increasing Aging Female Population

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulatory Framework that Delays the Approval of Products

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value – USD Million)

    1. 5.1 By Drug Class

      1. 5.1.1 Gonadotrophins

      2. 5.1.2 Aromatase Inhibitors

      3. 5.1.3 Selective Estrogen Receptor Modulators (SERMs)

      4. 5.1.4 Biguanides

      5. 5.1.5 Other Drug Classes

    2. 5.2 By End User

      1. 5.2.1 Male

      2. 5.2.2 Female

    3. 5.3 By Distribution Channel

      1. 5.3.1 Hospital Pharmacies

      2. 5.3.2 Retail Pharmacies

      3. 5.3.3 Other Distribution Channels

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 Ferring Pharmaceuticals Inc.

      3. 6.1.3 Merck KGaA

      4. 6.1.4 Pfizer Inc.

      5. 6.1.5 Novartis International AG

      6. 6.1.6 Bayer AG

      7. 6.1.7 Theramex

      8. 6.1.8 Mankind Pharma

      9. 6.1.9 Teva Pharmaceticals Industries

      10. 6.1.10 Livzon

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Infertility Drugs Market market is studied from 2019 - 2027.

The Global Infertility Drugs Market is growing at a CAGR of 6.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Ferring Pharmaceuticals Inc, Pfizer Inc., Merck KGaA, Novartis International AG, Bayer AG are the major companies operating in Global Infertility Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!